展示丙型肝炎病毒中和表位的嵌合乙型肝炎病毒S抗原病毒样颗粒所诱生抗体的中和效应
本研究在小鼠中评估展示HCV中和表位的嵌合HCV-HBV病毒样颗粒(VLPs)的免疫原性。BALB/c小鼠免疫纯化嵌合VLPs后,血清诱生抗HCV中和抗体,可中和不同异源1a、1b和2a基因型的HCV假病毒及细胞培养病毒,同时诱生抗HBsAg抗体。
要点
- 嵌合HCV-HBV VLPs在小鼠中诱生针对HCV的中和抗体。
- 小鼠血清可中和不同异源1a、1b和2a基因型的HCV假病毒及细胞培养病毒。
- 嵌合VLPs免疫同时诱生抗HBsAg抗体。
核心结论
- 嵌合HCV-HBV VLPs在小鼠中诱生针对HCV的中和抗体,可中和不同异源1a、1b和2a基因型的HCV假病毒及细胞培养病毒,并诱生抗HBsAg抗体。
- 本研究为开发HCV预防性中和表位疫苗及HCV-HBV双价预防性疫苗提供了新策略。
研究设计与样本
- 研究制备并纯化展示HCV中和表位的嵌合HCV-HBV VLPs,用纯化嵌合VLPs免疫BALB/c小鼠,分析血清中和抗体。
主要发现
- 嵌合VLPs在小鼠中诱生针对HCV的中和抗体。
- 小鼠血清中和了不同异源1a、1b和2a基因型的HCV假病毒感染及细胞培养病毒感染。
- 嵌合VLPs免疫还诱生了抗HBsAg抗体。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Hepatitis C virus (HCV) infection is a major public health problem despite effectual direct-acting antivirals (DAAs) therapy. Development of a prophylactic vaccine is essential to block spread of HCV infection. The HBV small surface antigen (HBsAg-S) can self-assemble into virus-like particles (VLPs), has higher immunogenicity and is used as a vaccine against HBV infections. Chimeric HBsAg-S proteins with foreign epitopes allow VLP formation and induce the specific humoral and cellular immune responses against the foreign proteins. In this study, we investigated the immune responses induced by chimeric VLPs with HCV neutralizing epitopes and HBV S antigen in mice. The chimeric HCV-HBV VLPs expressing neutralizing epitopes were prepared and purified. BALB/c mice were immunized with purified chimeric VLPs and the serum neutralizing antibodies were analyzed. We found that these chimeric VLPs induced neutralizing antibodies against HCV in mice. Additionally, the murine serum neutralized infections with HCV pseudoparticles and cell-cultured viruses derived from different heterologous 1a, 1b and 2a genotypes. We also found that immunization with chimeric VLPs induced anti-HBsAg antibodies. This study provides a novel strategy for development of a HCV prophylactic neutralizing epitope vaccine and a HCV-HBV bivalent prophylactic vaccine.
引用
- Wei S, Lei Y, Yang J, et al. Neutralization effects of antibody elicited by chimeric HBV S antigen viral-like particles presenting HCV neutralization epitopes. Vaccine. 2018. PMID: 29576303. doi:10.1016/j.vaccine.2018.03.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。